Clinical Takeaway
In this pilot trial of 20 adults with diagnosed insomnia disorder, a single oral dose of 10 mg THC combined with 200 mg CBD reduced total sleep time compared to placebo, suggesting that at least in the short term, this cannabinoid combination did not improve objective sleep duration. These findings highlight that anecdotal reports of cannabis improving sleep may not align with measurable EEG-based outcomes, and next-day alertness effects remain an important safety consideration. Patients using cannabinoids for insomnia should discuss realistic expectations and evidence limitations with their clinician before starting treatment.
#9 Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.
Citation: Suraev Anastasia et al.. Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.. Journal of sleep research. 2026. PMID: 40631525.
Design: 5 Journal: 0 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: 0
This pilot study provides the first high-resolution neurophysiological characterization of how a THC/CBD combination affects sleep architecture in patients with insomnia disorder, addressing a critical gap between widespread clinical use and limited objective data on efficacy and safety. The use of 256-channel high-density EEG enables detection of subtle changes in sleep stage transitions and cortical activity that standard polysomnography cannot capture, potentially revealing mechanisms underlying cannabinoid effects on sleep homeostasis. These findings are clinically important for establishing evidence-based dosing recommendations and identifying patient populations most likely to benefit from cannabinoid therapy while minimizing next-day impairment.
Methodological Considerations:
- Self-reported outcomes — recall and social-desirability bias risk
Abstract: Cannabinoids, particularly Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), have gained popularity as alternative sleep aids; however, their effects on sleep architecture and next-day function remain poorly understood. Here, in a pilot trial, we examined the effects of a single oral dose containing 10 mg THC and 200 mg CBD (THC/CBD) on objective sleep outcomes and next-day alertness using 256-channel high-density EEG in 20 patients with DSM-5 diagnosed insomnia disorder (16 female; mean (SD) age, 46.1 (8.6) years). We showed that THC/CBD decreased total sleep time (-24.5 min, p = 0.05, d = -0.5) with no change in wake after sleep onset (+10.7 min, p > 0.05) compared to placebo. THC/CBD also significantly decreased time spent in REM sleep (-33.9 min, p < 0.001, d = -1.5) and increased latency to REM sleep (+65.6 min, p = 0.008, d = 0.7). High-density EEG analysis revealed regional decreases in gamma activity during N2 sleep, and in delta activity during N3 sleep, and a regional increase in beta and alpha activity during REM sleep. While there was no observed change in next-day objective alertness, a small but significant increase in self-reported sleepiness was noted with THC/CBD (+0.42 points, p = 0.02, d = 0.22). No changes in subjective sleep quality, cognitive performance, or simulated driving performance were observed. These findings suggest that a single dose of cannabinoids, particularly THC, may acutely influence sleep, primarily by suppressing REM sleep, without noticeable next-day impairment (≥ 9 h post-treatment). Australian New Zealand Clinical Trial Registry (ACTRN12619000714189) https://www.anzctr.org.au/.
😴 This pilot study provides valuable objective neurophysiological data on acute THC/CBD effects in insomnia using high-density EEG, a methodologically stronger approach than self-reported outcomes alone, yet several important limitations warrant cautious interpretation. The small sample size of 20 patients, predominance of female participants (80%), and single-dose design limit generalizability to broader insomnia populations and chronic dosing scenarios that patients typically encounter in clinical practice. Additionally, the study does not adequately address individual variability in cannabinoid metabolism, prior cannabis exposure, or potential tolerance development with repeated use, all of which substantially influence real-world efficacy and safety. For clinicians considering cannabinoids for insomnia patients, this work suggests that objective sleep architecture changes are measurable and worth monitoring, but counseling patients should include acknowledgment that acute laboratory sleep improvements may not predict functional next-day performance or long-term therapeutic benefit, and individual therapeutic trials with careful symptom tracking remain essential until larger, longer-duration studies clarify